Developing vaccines and delivery methods for HIV treatment
Official title: Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancements
Funded at Wistar Institute · NIH-11011264 · Data updated 2026-11-12
This study is working on a new type of vaccine to help treat HIV, using special DNA technology, and will test it first in animals before trying it in people, all with the hope of boosting the body's defense against the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 8, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $205,553 |
| NIH project number | 5U19AI166916-03 |
| Project ID | NIH-11011264 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for HIV or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on creating and producing DNA vaccines aimed at treating HIV. The team at Inovio Pharmaceuticals will manufacture these vaccines using advanced techniques and ensure they meet clinical standards. They will also utilize a portable device for delivering the vaccine, which will be tested in animal models before moving to human trials. The goal is to develop effective immunogens that can stimulate the immune response against HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines for preventing and treating HIV infection.
How similar studies have gone: Previous research has shown promise in developing DNA vaccines for various diseases, indicating potential success for this approach in HIV treatment.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Smith, Trevor — Wistar Institute
- Study coordinator: Smith, Trevor
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.